Latest News

Engineered probiotic strain of Escherichia coli bacteria can reverse dangerously high levels of blood ammonia




Synlogic, Inc., a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Science Translational Medicine of clinical data from its Phase 1 clinical study in healthy volunteers and supporting preclinical data from its investigational Synthetic Biotic candidate, SYNB1020. The data support the continued development of SYNB1020 which is currently being evaluated in a Phase 1b/2a clinical trial in patients with cirrhosis and elevated blood ammonia.

Source link





Related posts

Medical News Today: Schizophrenia: Restoring brain circuitry to improve symptoms

Newsemia

Around 1,500 MERS cases, 500 deaths averted since 2016

Newsemia

Yemen faces new surge in cholera cases: UN

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy